Avalyn Pharma Inc. Chief Medical Officer Howard Lazarus filed a Form 4 on November 19, 2026, disclosing transactions in common stock executed on November 17, 2026, under a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Howard Lazarus exercised a stock option for 13,300 shares of common stock at an exercise price of $4.62 per share on November 17, 2026.
  • Three separate sales: Lazarus sold all 13,300 acquired shares across three tranches: 11,023 shares at a weighted average of $27.8001, 2,066 shares at a weighted average of $28.2722, and 211 shares at a weighted average of $29.2722.
  • Resulting ownership: Following all reported transactions, Lazarus held 0 shares of common stock directly.
  • 10b5-1 plan: All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.
  • Remaining derivative securities: Lazarus retains 257,198 stock options with an exercise price of $4.62 and an expiration date of January 24, 2034.

Lazarus Howard's November 17 Option Exercise and Sale Transactions at Avalyn Pharma

According to the Form 4 filed with the SEC on November 19, 2026, Howard Lazarus, Chief Medical Officer of Avalyn Pharma Inc. (NASDAQ:AVLN), exercised stock options covering 13,300 shares of common stock on November 17, 2026, at an exercise price of $4.62 per share. The filing indicates these transactions were carried out under a Rule 10b5-1 trading plan that Lazarus adopted on July 30, 2026.

The filing reports that immediately following the exercise, Lazarus disposed of all 13,300 shares through three separate sale transactions on the same date. The first tranche of 11,023 shares was sold at a weighted average price of $27.8001, with individual transactions ranging from $27.11 to $28.10 per share. The second tranche of 2,066 shares was sold at a weighted average price of $28.2722, with individual transactions ranging from $28.11 to $29.03 per share. The third and final tranche of 211 shares was sold at a weighted average price of $29.2722, with individual transactions ranging from $29.13 to $29.37 per share. The filing notes that full price-by-price detail for each tranche is available upon request to the issuer, any security holder, or SEC staff.

After these transactions, the filing discloses that Lazarus holds 0 shares of common stock directly. However, he retains 257,198 stock options (right to buy) with an exercise price of $4.62 and an expiration date of January 24, 2034. According to the filing, 25% of the shares underlying the option vested and became exercisable on August 7, 2024, with the remaining 75% vesting in thirty-six substantially equal monthly installments thereafter, subject to continued service. The form was signed by Douglas Carlson as Attorney-in-Fact on November 19, 2026.

What Was Disclosed

The filing disclosed an option exercise of 13,300 shares at $4.62 and the same-day sale of all those shares across three price tranches, all conducted under a Rule 10b5-1 plan. Lazarus's direct common stock holding after these transactions is 0 shares.